Chengdu Baiyu Pharmaceutical Co., Ltd.
3 clinical trials · Sponsor
◉ Watch Chengdu Baiyu Pharmaceutical Co., Ltd.
| Record | Firm | Date |
|---|---|---|
| A Phase Ib/II Study of BY101298 , an Oral DNA-PK Inhibitor, Combined with Radiotherapy in Patients with Malignant Solid Tumors (NCT06524804) | Chengdu Baiyu Pharmaceutical Co., Ltd. | 2024-05-15 |
| A Phase l Study of By101921, an Oral PARP7 Inhibitor, in Patients With Advanced Solid Tumors (NCT06433726) | Chengdu Baiyu Pharmaceutical Co., Ltd. | 2024-03-11 |
| A Phase l Study of By101298, an Oral DNA-PK Inhibitor, in Patients With Advanced Solid Tumors (NCT06462716) | Chengdu Baiyu Pharmaceutical Co., Ltd. | 2023-04-25 |
Track Chengdu Baiyu Pharmaceutical Co., Ltd. automatically
Every clearance here is in the API, with alerts when new ones post.